Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
April 08, 2024 11:15 ET
|
Imbria Pharmaceuticals Inc.
– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis
November 14, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics,...
Hypertrophic Cardiomyopathy Market to Hit US$ 1.35 Billion by 2031| Exclusive Report by Growth Plus Reports
June 22, 2023 09:54 ET
|
Growth Plus Reports
Newark, New Castle, USA, June 22, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for hypertrophic cardiomyopathy in 2022 to be worth US$ 1.12 billion, and it is...
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
May 17, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
December 05, 2022 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Hypertrophic Cardiomyopathy Therapeutics Market To Reach USD 1.42 Billion By 2027 | Reports and Data
April 02, 2020 11:50 ET
|
Reports and Data
New York, April 02, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and...
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
November 04, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
Most Americans With HCM Live Normal Life Spans
November 08, 2011 11:00 ET
|
American Heart Association
Statement Highlights:
Hypertrophic cardiomyopathy (HCM) is a treatable disease compatible with normal longevity.
HCM is the most common inherited cardiac disease, occurring in one per 500...